PDF herunterladen
Semin Liver Dis 2017; 37(01): 001-010
DOI: 10.1055/s-0036-1597816
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Regression of Liver Fibrosis

Lara Campana
1   Centre for Inflammation Research and Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
2   MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
,
John P. Iredale
3   Senate House, University of Bristol, Bristol, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Februar 2017 (online)

    Lizenzen und Reprints

Abstract

Liver fibrosis is the final common pathway of chronic or iterative liver damage. Advanced chronic fibrosis is described as cirrhosis with a loss of architecture and attendant functional failure and the development of life-threatening complications. However, compelling evidence from rodent models and human studies indicates that if the injury is removed liver fibrosis is reversible. Hepatocytes, activated hepatic stellate cells, endothelial and immune cells, particularly macrophages, cooperate in the establishment and resolution of liver fibrosis. Here the authors provide a short overview of the mechanisms regulating the profibrotic and proresolution response, with the aim of highlighting potential new therapeutic targets. Liver disease is a major unmet medical need; currently, the sole approaches are the withdrawal of the injurious stimulus and liver transplantation. The authors conclude with a brief review of the feasibility of macrophage-based cell therapy for liver fibrosis.

Keywords

liver - fibrosis - metalloproteases - macrophages - hepatic stellate cells
 

  • References

  • 1 Iredale JP, Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology 2014; 146 (5) 1160-1164
    CrossrefPubMedGoogle Scholar
  • 2 Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14 (3) 181-194
    CrossrefPubMedGoogle Scholar
  • 3 Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007; 112 (5) 265-280
    CrossrefPubMedGoogle Scholar
  • 4 Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117 (3) 539-548
    CrossrefPubMedGoogle Scholar
  • 5 Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 2013; 1832 (7) 876-883
    CrossrefPubMedGoogle Scholar
  • 6 Aravinthan AD, Alexander GJ. Senescence in chronic liver disease: is the future in aging?. J Hepatol 2016; 65 (4) 825-834
    CrossrefPubMedGoogle Scholar
  • 7 Knolle PA, Wohlleber D. Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol 2016; 13 (3) 347-353
    CrossrefPubMedGoogle Scholar
  • 8 Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol 2016; 18 (3) 246-254
    CrossrefPubMedGoogle Scholar
  • 9 Schweiger PJ, Jensen KB. Modeling human disease using organotypic cultures. Curr Opin Cell Biol 2016; 43: 22-29
    CrossrefPubMedGoogle Scholar
  • 10 Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol 2015; 62 (1, Suppl) S157-S169
    CrossrefPubMedGoogle Scholar
  • 11 Liu Y, Meyer C, Xu C , et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol 2013; 304 (5) G449-G468
    CrossrefPubMedGoogle Scholar
  • 12 Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65 (3) 305-311
    PubMedGoogle Scholar
  • 13 Greenhalgh SN, Conroy KP, Henderson NC. Cre-ativity in the liver: transgenic approaches to targeting hepatic nonparenchymal cells. Hepatology 2015; 61 (6) 2091-2099
    CrossrefPubMedGoogle Scholar
  • 14 Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328 (25) 1828-1835
    CrossrefPubMedGoogle Scholar
  • 15 Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985; 82 (24) 8681-8685
    CrossrefPubMedGoogle Scholar
  • 16 Issa R, Zhou X, Constandinou CM , et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126 (7) 1795-1808
    CrossrefPubMedGoogle Scholar
  • 17 Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29 (1) 43-54
    CrossrefPubMedGoogle Scholar
  • 18 Consolo M, Amoroso A, Spandidos DA, Mazzarino MC. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med 2009; 24 (2) 143-152
    PubMedGoogle Scholar
  • 19 Docherty AJ, O'Connell J, Crabbe T, Angal S, Murphy G. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 1992; 10 (6) 200-207
    CrossrefPubMedGoogle Scholar
  • 20 Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46 (5) 955-975
    CrossrefPubMedGoogle Scholar
  • 21 Yoshiji H, Kuriyama S, Yoshii J , et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36 (4 Pt 1): 850-860
    CrossrefPubMedGoogle Scholar
  • 22 Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16 (11) 1321-1329
    CrossrefPubMedGoogle Scholar
  • 23 Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015; 148 (1) 30-36
    CrossrefPubMedGoogle Scholar
  • 24 Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int 2014; 34 (6) 834-843
    CrossrefPubMedGoogle Scholar
  • 25 Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C. Origins and functions of liver myofibroblasts. Biochim Biophys Acta 2013; 1832 (7) 948-954
    CrossrefPubMedGoogle Scholar
  • 26 Forbes SJ, Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol 2011; 25 (2) 207-217
    PubMedGoogle Scholar
  • 27 Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 (Suppl. 01) S26
    CrossrefPubMedGoogle Scholar
  • 28 Preaux AM, D'ortho MP, Bralet MP, Laperche Y, Mavier P. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002; 36 (3) 615-622
    CrossrefPubMedGoogle Scholar
  • 29 Wright MC, Issa R, Smart DE , et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121 (3) 685-698
    CrossrefPubMedGoogle Scholar
  • 30 Troeger JS, Mederacke I, Gwak GY , et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012; 143 (4) 1073-83.e22
    CrossrefPubMedGoogle Scholar
  • 31 Kisseleva T, Cong M, Paik Y , et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012; 109 (24) 9448-9453
    CrossrefPubMedGoogle Scholar
  • 32 Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21 (Suppl. 03) S84-S87
    CrossrefPubMedGoogle Scholar
  • 33 Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation 2016; S0301-4681(15)30100-6
    PubMedGoogle Scholar
  • 34 Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59 (3) 583-594
    CrossrefPubMedGoogle Scholar
  • 35 Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143 (5) 1158-1172
    CrossrefPubMedGoogle Scholar
  • 36 Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008; 20 (5) 518-523
    CrossrefPubMedGoogle Scholar
  • 37 Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010; 51 (2) 621-632
    CrossrefPubMedGoogle Scholar
  • 38 Sitia G, Iannacone M, Müller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007; 81 (1) 100-107
    CrossrefPubMedGoogle Scholar
  • 39 Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323 (5922): 1722-1725
    CrossrefPubMedGoogle Scholar
  • 40 Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol 2014; 20 (9) 2168-2175
    CrossrefPubMedGoogle Scholar
  • 41 Thakur V, Pritchard MT, McMullen MR, Wang Q, Nagy LE. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol 2006; 79 (6) 1348-1356
    CrossrefPubMedGoogle Scholar
  • 42 Kishore R, McMullen MR, Cocuzzi E, Nagy LE. Lipopolysaccharide-mediated signal transduction: stabilization of TNF-alpha mRNA contributes to increased lipopolysaccharide-stimulated TNF-alpha production by Kupffer cells after chronic ethanol feeding. Comp Hepatol 2004; 3 (Suppl. 01) S31
    CrossrefPubMedGoogle Scholar
  • 43 Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G. The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol 2009; 183 (2) 1320-1327
    CrossrefPubMedGoogle Scholar
  • 44 Rensen SS, Slaats Y, Driessen A , et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 2009; 50 (6) 1809-1817
    CrossrefPubMedGoogle Scholar
  • 45 Gao B, Seki E, Brenner DA , et al. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300 (4) G516-G525
    CrossrefPubMedGoogle Scholar
  • 46 Roychowdhury S, McMullen MR, Pritchard MT , et al. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology 2009; 49 (4) 1326-1334
    CrossrefPubMedGoogle Scholar
  • 47 Park SH, Kim BI, Yun JW , et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004; 19 (6) 694-698
    CrossrefPubMedGoogle Scholar
  • 48 Wang CC, Lin SK, Tseng YF , et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24 (8) 1411-1416
    CrossrefPubMedGoogle Scholar
  • 49 Zhang Z, Lin C, Peng L , et al. High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells. Life Sci 2012; 91 (5–6): 207-212
    CrossrefPubMedGoogle Scholar
  • 50 Dangi A, Sumpter TL, Kimura S , et al. Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. J Immunol 2012; 188 (8) 3667-3677
    CrossrefPubMedGoogle Scholar
  • 51 Dunham RM, Thapa M, Velazquez VM , et al. Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J Immunol 2013; 190 (5) 2009-2016
    CrossrefPubMedGoogle Scholar
  • 52 Langhans B, Alwan AW, Krämer B , et al. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol 2015; 62 (2) 398-404
    CrossrefPubMedGoogle Scholar
  • 53 Thomas JA, Pope C, Wojtacha D , et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53 (6) 2003-2015
    CrossrefPubMedGoogle Scholar
  • 54 Saito JM, Bostick MK, Campe CB, Xu J, Maher JJ. Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis. Hepatol Res 2003; 25 (2) 180-191
    CrossrefPubMedGoogle Scholar
  • 55 Harty MW, Muratore CS, Papa EF , et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol 2010; 176 (3) 1271-1281
    CrossrefPubMedGoogle Scholar
  • 56 Duffield JS, Forbes SJ, Constandinou CM , et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115 (1) 56-65
    CrossrefPubMedGoogle Scholar
  • 57 Ramachandran P, Iredale JP. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 2012; 105 (9) 813-817
    CrossrefPubMedGoogle Scholar
  • 58 Falasca L, Bergamini A, Serafino A, Balabaud C, Dini L. Human Kupffer cell recognition and phagocytosis of apoptotic peripheral blood lymphocytes. Exp Cell Res 1996; 224 (1) 152-162
    CrossrefPubMedGoogle Scholar
  • 59 Dini L, Pagliara P, Carlà EC. Phagocytosis of apoptotic cells by liver: a morphological study. Microsc Res Tech 2002; 57 (6) 530-540
    CrossrefPubMedGoogle Scholar
  • 60 Ramachandran P, Pellicoro A, Vernon MA , et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012; 109 (46) E3186-E3195
    CrossrefPubMedGoogle Scholar
  • 61 Bain CC, Hawley CA, Garner H , et al. Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities. Nat Commun 2016; 7: s11852
    CrossrefPubMedGoogle Scholar
  • 62 Scott CL, Zheng F, De Baetselier P , et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun 2016; 7: 10321
    CrossrefPubMedGoogle Scholar
  • 63 Zigmond E, Samia-Grinberg S, Pasmanik-Chor M , et al. Infiltrating monocyte-derived macrophages and resident Kupffer cells display different ontogeny and functions in acute liver injury. J Immunol 2014; 193 (1) 344-353
    CrossrefPubMedGoogle Scholar
  • 64 Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30 (3) 245-257
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Karlmark KR, Weiskirchen R, Zimmermann HW , et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50 (1) 261-274
    CrossrefPubMedGoogle Scholar
  • 66 Ehling J, Bartneck M, Wei X , et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014; 63 (12) 1960-1971
    CrossrefPubMedGoogle Scholar
  • 67 Yang L, Kwon J, Popov Y , et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146 (5) 1339-50.e1
    CrossrefPubMedGoogle Scholar
  • 68 Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997; 94 (20) 10663-10668
    CrossrefPubMedGoogle Scholar
  • 69 Wynn TA, Cheever AW, Jankovic D , et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376 (6541): 594-596
    CrossrefPubMedGoogle Scholar
  • 70 Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4 (8) 583-594
    CrossrefPubMedGoogle Scholar
  • 71 Rolla S, Alchera E, Imarisio C , et al. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin Sci (Lond) 2016; 130 (3) 193-203
    PubMedGoogle Scholar
  • 72 Oh K, Seo MW, Kim YW, Lee DS. Osteopontin potentiates pulmonary inflammation and fibrosis by modulating IL-17/IFN-γ-secreting T-cell ratios in bleomycin-treated mice. Immune Netw 2015; 15 (3) 142-149
    CrossrefPubMedGoogle Scholar
  • 73 Angaswamy N, Tiriveedhi V, Sarma NJ , et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013; 74 (11) 1478-1485
    CrossrefPubMedGoogle Scholar
  • 74 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517
    CrossrefPubMedGoogle Scholar
  • 75 Katz SC, Ryan K, Ahmed N , et al. Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol 2011; 187 (3) 1150-1156
    CrossrefPubMedGoogle Scholar
  • 76 Turner JD, Jenkins GR, Hogg KG , et al. CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2 granulomatous pathology caused by schistosome infection. PLoS Negl Trop Dis 2011; 5 (8) e1269
    CrossrefPubMedGoogle Scholar
  • 77 Langhans B, Krämer B, Louis M , et al. Intrahepatic IL-8 producing Foxp3+CD4+ regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol 2013; 59 (2) 229-235
    CrossrefPubMedGoogle Scholar
  • 78 Safadi R, Ohta M, Alvarez CE , et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127 (3) 870-882
    CrossrefPubMedGoogle Scholar
  • 79 Novobrantseva TI, Majeau GR, Amatucci A , et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005; 115 (11) 3072-3082
    CrossrefPubMedGoogle Scholar
  • 80 Geissmann F, Cameron TO, Sidobre S , et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3 (4) e113
    CrossrefPubMedGoogle Scholar
  • 81 Wehr A, Baeck C, Heymann F , et al. Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis. J Immunol 2013; 190 (10) 5226-5236
    CrossrefPubMedGoogle Scholar
  • 82 Sheel M, Beattie L, Frame TC , et al. IL-17A-producing γδ T cells suppress early control of parasite growth by monocytes in the liver. J Immunol 2015; 195 (12) 5707-5717
    CrossrefPubMedGoogle Scholar
  • 83 Liang Y, Jie Z, Hou L , et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J Immunol 2013; 190 (11) 5666-5675
    CrossrefPubMedGoogle Scholar
  • 84 McHedlidze T, Waldner M, Zopf S , et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39 (2) 357-371
    CrossrefPubMedGoogle Scholar
  • 85 Verhulst S, Best J, van Grunsven LA, Dollé L. Advances in hepatic stem/progenitor cell biology. EXCLI J 2015; 14: 33-47
    PubMedGoogle Scholar
  • 86 Marshall A, Rushbrook S, Davies SE , et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128 (1) 33-42
    CrossrefPubMedGoogle Scholar
  • 87 Tachtatzis PM, Marshall A, Aravinthan A , et al. Correction: chronic hepatitis B virus infection: the relation between hepatitis B antigen expression, telomere length, senescence, inflammation and fibrosis. PLoS One 2015; 10 (7) e0134315
    CrossrefPubMedGoogle Scholar
  • 88 Aravinthan A, Pietrosi G, Hoare M , et al. Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver disease. PLoS One 2013; 8 (9) e72904
    CrossrefPubMedGoogle Scholar
  • 89 Richardson MM, Jonsson JR, Powell EE , et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133 (1) 80-90
    CrossrefPubMedGoogle Scholar
  • 90 Wood MJ, Gadd VL, Powell LW, Ramm GA, Clouston AD. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology 2014; 59 (3) 848-857
    CrossrefPubMedGoogle Scholar
  • 91 Yang S, Koteish A, Lin H , et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 2004; 39 (2) 403-411
    CrossrefPubMedGoogle Scholar
  • 92 Sadri AR, Jeschke MG, Amini-Nik S. Advances in liver regeneration: revisiting hepatic stem/progenitor cells and their origin. Stem Cells Int 2016; 2016 (16) 7920897
    PubMedGoogle Scholar
  • 93 Kaur S, Siddiqui H, Bhat MH. Hepatic progenitor cells in action: liver regeneration or fibrosis?. Am J Pathol 2015; 185 (9) 2342-2350
    CrossrefPubMedGoogle Scholar
  • 94 Forbes SJ, Newsome PN. Liver regeneration - mechanisms and models to clinical application. Nat Rev Gastroenterol Hepatol 2016; 13 (8) 473-485
    CrossrefPubMedGoogle Scholar
  • 95 Lu WY, Bird TG, Boulter L , et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat Cell Biol 2015; 17 (8) 971-983
    CrossrefPubMedGoogle Scholar
  • 96 Boulter L, Govaere O, Bird TG , et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 2012; 18 (4) 572-579
    CrossrefPubMedGoogle Scholar
  • 97 Caralt M, Velasco E, Lanas A, Baptista PM. Liver bioengineering: from the stage of liver decellularized matrix to the multiple cellular actors and bioreactor special effects. Organogenesis 2014; 10 (2) 250-259
    CrossrefPubMedGoogle Scholar
  • 98 Sudo R. Multiscale tissue engineering for liver reconstruction. Organogenesis 2014; 10 (2) 216-224
    CrossrefPubMedGoogle Scholar
  • 99 Smedsrød B. Clearance function of scavenger endothelial cells. Comp Hepatol 2004; 3 (Suppl. 01) S22
    CrossrefPubMedGoogle Scholar
  • 100 Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88 (1) 125-172
    CrossrefPubMedGoogle Scholar
  • 101 Bird TG, Lu WY, Boulter L , et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A 2013; 110 (16) 6542-6547
    CrossrefPubMedGoogle Scholar
  • 102 Moore JK, Mackinnon AC, Wojtacha D , et al. Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study. Cytotherapy 2015; 17 (11) 1604-1616
    CrossrefPubMedGoogle Scholar
  • 103 Senju S, Koba C, Haruta M , et al. Application of iPS cell-derived macrophages to cancer therapy. OncoImmunology 2014; 3 (1) e27927
    CrossrefPubMedGoogle Scholar
  • 104 King A, Barton D, Beard HA , et al. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMJ Open 2015; 5 (3) e007700
    CrossrefPubMedGoogle Scholar
  • 105 Friedman S, Sanyal A, Goodman Z , et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials 2016; 47: 356-365
    CrossrefPubMedGoogle Scholar
  • 106 Lefebvre E, Moyle G, Reshef R , et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 2016; 11 (6) e0158156
    CrossrefPubMedGoogle Scholar
  • 107 Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis. J Gastroenterol 2017; 52 (2) 129-140
    CrossrefPubMedGoogle Scholar
  • 108 Dobie R, Henderson NC. Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis. F1000 Res 2016; 5: F1000 Faculty Rev-1749
    PubMedGoogle Scholar